MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 563781 | Name: DOOT-2d

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DOOT-2d is a selective MAO-B inhibitor.

Chemical Structure

DOOT-2d
DOOT-2d
CAS#1522345-35-2

Theoretical Analysis

MedKoo Cat#: 563781

Name: DOOT-2d

CAS#: 1522345-35-2

Chemical Formula: C15H13FO3

Exact Mass: 260.0849

Molecular Weight: 260.26

Elemental Analysis: C, 69.22; H, 5.03; F, 7.30; O, 18.44

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
DOOT-2d; DOOT2d; DOOT 2d
IUPAC/Chemical Name
1-(4-((3-Fluorobenzyl)oxy)-2-hydroxyphenyl)ethan-1-one
InChi Key
UFWGBYKUPYCCBE-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H13FO3/c1-10(17)14-6-5-13(8-15(14)18)19-9-11-3-2-4-12(16)7-11/h2-8,18H,9H2,1H3
SMILES Code
CC(C1=CC=C(OCC2=CC=CC(F)=C2)C=C1O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 260.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chan HH, Tse MK, Kumar S, Zhuo L. A novel selective MAO-B inhibitor with neuroprotective and anti-Parkinsonian properties. Eur J Pharmacol. 2018 Jan 5;818:254-262. doi: 10.1016/j.ejphar.2017.10.023. Epub 2017 Oct 17. PubMed PMID: 29050969. 2: Fowler JS, Logan J, Volkow ND, Shumay E, McCall-Perez F, Jayne M, Wang GJ, Alexoff DL, Apelskog-Torres K, Hubbard B, Carter P, King P, Fahn S, Gilmor M, Telang F, Shea C, Xu Y, Muench L. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Neuropsychopharmacology. 2015 Feb;40(3):650-7. doi: 10.1038/npp.2014.214. Epub 2014 Sep 24. PubMed PMID: 25249059; PubMed Central PMCID: PMC4289953. 3: Mishra N, Sasmal D. Modulations of brain amines and dopaminergic behavior by a novel, reversible and selective MAO-B inhibitor. Brain Res. 2012 Aug 27;1470:45-51. doi: 10.1016/j.brainres.2012.06.037. Epub 2012 Jul 3. PubMed PMID: 22765918. 4: Unzeta M, Sanz E. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease. Int Rev Neurobiol. 2011;100:217-36. doi: 10.1016/B978-0-12-386467-3.00011-X. Review. PubMed PMID: 21971010. 5: deMarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I; Parkinson Study Group TEMPO; PRESTO Tyramine Substudy Investigators and Coordinators. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006 Oct;21(10):1716-21. PubMed PMID: 16856145. 6: Youdim MB, Maruyama W, Naoi M. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc). 2005 Jun;41(6):369-91. Review. PubMed PMID: 16110345. 7: Magyar K, Szende B. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology. 2004 Jan;25(1-2):233-42. Review. PubMed PMID: 14697898. 8: Palfreyman MG, McDonald IA, Zreika M, Cremer G, Haegele KD, Bey P. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease. J Neural Transm Suppl. 1993;40:101-11. PubMed PMID: 8294896. 9: Engberg G, Elebring T, Nissbrandt H. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J Pharmacol Exp Ther. 1991 Nov;259(2):841-7. PubMed PMID: 1658311. 10: Rose S, Nomoto M, Jackson EA, Gibb WR, Jenner P, Marsden CD. Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets. Neuropharmacology. 1989 Nov;28(11):1211-6. PubMed PMID: 2512516. 11: Da Prada M, Kettler R, Keller HH, Bonetti EP, Imhof R. Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP. Adv Neurol. 1987;45:175-8. PubMed PMID: 2881442.